Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
5.4
3.9
Journals
JCM
Special Issues
Updates on Treatment of Esophageal Cancer
share announcement

Updates on Treatment of Esophageal Cancer

A special issue of Journal of Clinical Medicine (ISSN 2077-0383).

Deadline for manuscript submissions: closed (30 April 2016)

Special Issue Editor

Prof. Dr. Manish A. Shah

E-Mail Website
Guest Editor
Solid Tumor/GI Oncology Practice, Weill Cornell Medical College of Cornell University/NewYork-Presbyterian Hospital, 1305 York Avenue, 12th Floor, New York, NY 10021, USA
Interests: drug development; biomarkers; angiogenesis; signal transduction; genetic syndromes; symptom management; comparative effectiveness; immuno-oncology; tumor biology

Special Issue Information

Dear Colleagues,

We are truly entering a new era in the management of upper GI malignancies. There is an emergence of new targeted therapies, including recent-approved drugs that target HER2 and antiangiogenic therapy, as well as exciting preliminary data involving immune checkpoint inhibitors, and other pathways, including PTEN/AKT, stem cell inhibitors, and FGF inhibitors. In parallel to this remarkable growth of targeted options, we have improved our classification of both esophageal and gastric cancers, based on molecular profiling. As a result, we are slowly improving outcomes in these diseases. This Special Issue of the Journal of Clinical Medicine will focus on “Advances in Esophagus Cancer”, including cancers of the gastroesophageal junction. I invite you to submit your article with a special focus on any of the following topics:

  • novel pathways in esophageal/GEJ carcinoma
  • molecular profiling of esophageal/GEJ carcinoma
  • tumor microenvironment
  • microbiome
  • premalignant conditions and their progression to malignancy
  • new drugs and drug targets
  • early phase clinical trials
  • disease heterogeneity—both tumor and global
  • comparative effectiveness research

Prof. Dr. Manish A. Shah
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Journal of Clinical Medicine is an international peer-reviewed open access semimonthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2600 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • angiogenesis
  • HER2
  • PD1, PDL1
  • FGF
  • MET
  • molecular profiling
  • phase 1, phase 2
  • Barrett’s esophagus
  • microbiome
  • tumor infiltrating lymphocytes
  • tumor microenvironment

Published Papers (3 papers)

Download All Papers
Order results
Result details
Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:

Review

452 KiB  
Review
The Future Prospects of Immune Therapy in Gastric and Esophageal Adenocarcinoma
by Walid L. Shaib, Jean Paul A. Nammour, Harpaul Gill, Mayur Mody and Nabil F. Saba
J. Clin. Med. 2016, 5(11), 100; https://doi.org/10.3390/jcm5110100 - 14 Nov 2016
Cited by 8 | Viewed by 4466
Abstract
The prognosis of esophageal cancers is poor and novel approaches are urgently needed. Despite improvements in outcomes with transtuzumab and ramucirumab, these improvements added an average of only 2 to 3 months with a median overall survival reported to be around 1 year. [...] Read more.
The prognosis of esophageal cancers is poor and novel approaches are urgently needed. Despite improvements in outcomes with transtuzumab and ramucirumab, these improvements added an average of only 2 to 3 months with a median overall survival reported to be around 1 year. Comprehensive genomic sequencing has defined some molecular alterations with potential targets, but the majority of patients still do not benefit from druggable targets. Breakthroughs in immune checkpoint blockade have provided new therapeutic options in many cancers. Programmed death ligand 1 (PDL1) overexpression, a possible biomarker predicting response to immune checkpoint inhibitors, approaches forty percent in esophageal and gastric cancers. Translational and molecular studies have shown that esophageal cancers are possible candidate malignancies for immune checkpoint inhibition. In this review, we plan to highlight the mechanisms, preclinical, and early clinical data that provide insight on the role of immune therapeutics in esophageal cancers. Full article
(This article belongs to the Special Issue Updates on Treatment of Esophageal Cancer)
►▼ Show Figures

Graphical abstract

210 KiB  
Review
Advances in Radiotherapy Management of Esophageal Cancer
by Vivek Verma, Amy C. Moreno and Steven H. Lin
J. Clin. Med. 2016, 5(10), 91; https://doi.org/10.3390/jcm5100091 - 21 Oct 2016
Cited by 35 | Viewed by 5728
Abstract
Radiation therapy (RT) as part of multidisciplinary oncologic care has been marked by profound advancements over the past decades. As part of multimodality therapy for esophageal cancer (EC), a prime goal of RT is to minimize not only treatment toxicities, but also postoperative [...] Read more.
Radiation therapy (RT) as part of multidisciplinary oncologic care has been marked by profound advancements over the past decades. As part of multimodality therapy for esophageal cancer (EC), a prime goal of RT is to minimize not only treatment toxicities, but also postoperative complications and hospitalizations. Herein, discussion commences with the historical approaches to treating EC, including seminal trials supporting multimodality therapy. Subsequently, the impact of RT techniques, including three-dimensional conformal RT, intensity-modulated RT, and proton beam therapy, is examined through available data. We further discuss existing data and the potential for further development in the future, with an appraisal of the future outlook of technological advancements of RT for EC. Full article
(This article belongs to the Special Issue Updates on Treatment of Esophageal Cancer)
511 KiB  
Review
Immunotherapy for Gastroesophageal Cancer
by Emily F. Goode and Elizabeth C. Smyth
J. Clin. Med. 2016, 5(10), 84; https://doi.org/10.3390/jcm5100084 - 22 Sep 2016
Cited by 43 | Viewed by 9619
Abstract
Survival for patients with advanced oesophageal and stomach cancer is poor; together these cancers are responsible for more than a million deaths per year globally. As chemotherapy and targeted therapies such as trastuzumab and ramucirumab result in modest improvements in survival but not [...] Read more.
Survival for patients with advanced oesophageal and stomach cancer is poor; together these cancers are responsible for more than a million deaths per year globally. As chemotherapy and targeted therapies such as trastuzumab and ramucirumab result in modest improvements in survival but not long-term cure for such patients, development of alternative treatment approaches is warranted. Novel immunotherapy drugs such as checkpoint inhibitors have been paradigm changing in melanoma, non-small cell lung cancer and urothelial cancers. In this review, we assess the early evidence for efficacy of immunotherapy in patients with gastroesophageal cancer in addition to considering biomarkers associated with response to these treatments. Early results of Anti- Programmed Cell Death Protein-1 (anti-PD-1), anti-PD-L1 and anti-Cytotoxic T-lymphocyte assosciated protein-4 (anti-CTLA4) trials are examined, and we conclude with a discussion on the future direction for immunotherapy for gastroesophageal cancer patients. Full article
(This article belongs to the Special Issue Updates on Treatment of Esophageal Cancer)
►▼ Show Figures

Graphical abstract

Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:
 
Displaying articles 1-3
Back to TopTop